This study will evaluate the association of non-alcoholic fatty liver disease and diabetes mellitus. Patients presenting in our clinic with Diabetes mellitus type 1 or 2 will receive the following examination: * Transient Elastography and Controlled Attenuation Parameter using the FibroScan * blood examination including biochemical markers The statistically calculated sample size needed is 340 patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
340
University Hospital Frankfurt
Frankfurt am Main, Hesse, Germany
Steatosis
• Evaluating the presence of liver steatosis in patients with diabetes mellitus using the ultrasound-based method "Controlled Attenuation Parameter", which is integrated in the FibroScan machine and can non-invasively quantify liver steatosis (Steatosis fibrosis scores I-III \[ Designated as safety issue: No \]; Steatosis scores: 0 = \<5% I = 5-33% II = 33-66% III = \>66%)
Time frame: one day
Fibrosis
• Evaluation of the prevalence of liver fibrosis using transientelastography (FibroScan) and serological markers in patients with diabetes mellitus (Liver fibrosis scores I-IV (METAVIR) \[ Designated as safety issue: No \]; METAVIR fibrosis scores: I = mild fibrosis II = significant fibrosis III = advanced fibrosis IV = cirrhosis)
Time frame: one day
Steatosis (serum)
• Evaluating the prevalence of liver steatosis using serum steatosis markers in patients with diabetes mellitus
Time frame: one day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.